Pharma Germany outlines the future: Focus on costs and production

Pharma Germany and the effects of the new wastewater guideline on the health system

The recently decided European wastewater guideline has caused great concern in the German pharmaceutical industry. Jörg Wienczorek, CEO of Pharma Germany, warned of the financial consequences for the health system at the first ordinary general meeting of the association in Berlin. The guideline requires the introduction of a fourth sewage level in sewage treatment plants, which could put a lot of strain on the industry.

This sewage level could significantly increase up to 2 billion euros annually, according to Wieczorek, and thus significantly increase prices for important medications, especially antibiotics and analgesics. The pharmaceutical industry sees Already under considerable price pressure, and an additional burden could lead to an tightening of the situation in health care.

Special attention was paid to the effects of this guideline on the population. Wieczorek reported on a representative survey in which 78 percent of those surveyed believe that the costs for the elimination of wastewater pollution should be borne by the causers. In addition, 60 percent of the population rejected higher prices for medication that could result from the implementation of the directive.

These survey results illustrate the resistance of the population against higher drug prices and throw a light on the area of ​​tension between environmental requirements and the financial burden on the health system. The need for a strong representation of the pharmaceutical industry was emphasized by Wieczorek to display the concerns of industry and to ensure that the creation of rules for wastewater and health reforms is not carried out on the patient's back.

The importance of the German pharmaceutical industry should not be underestimated. It has a significant influence on the economy and offers numerous jobs. Wieczorek emphasized that the realignment of Pharma Germany aims to increase the visibility and relevance of this industry. This is particularly important for medium -sized companies that are not among the large international corporations, but are extremely important for the regional economic structure.

As part of this realignment, Pharma Germany will also promote political and public discussion culture about the challenges that the pharmaceutical industry faces. The challenges resulting from the European Wastewater Directive could represent a turning point in the cooperation between the pharmaceutical industry, politics and society.

Overall, it can be seen that the discussion about the wastewater guideline affects not only the pharmaceutical industry, but also the broader society. The balance between environmental protection and the guarantee of affordable health care will be of crucial importance.

In summary, it should be noted that the new European Wastewater Directive could initiate a far -reaching debate about the financial future of the German health system. Pharma Germany's commitment to clarify and represent the interests of the industry will be important in the coming months, since it leads to the maintenance of a functional and accessible health system that the population is dependent on.